SOLVENTUM CORPORATION (SOLV): what the price assumes

boothcheck covers SOLVENTUM CORPORATION (SOLV) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-11.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/SOLV

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by earnings-power value, while asset-based/growth-DCF land below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Earnings Families that call it expensive: Asset, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.0%); the inversion above states its own rate.

Per-Model Detail (n=5)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Solventum sells wound care, dental products, and hospital coding software: three segments that did $8,325 million of worldwide sales in 2025 ($4,668 million U.S., $3,657 million international) at a 25.5% trailing operating margin, yet the stock trades at roughly nine times operating income. [FY2025 10-K, accession 0001964738-26-000007]
• The separation from 3M still runs through the cost line: MedSurg profitability was squeezed by "higher product costs due to tariffs, logistics and a full year of supply agreement mark-ups from 3M" [FY2025 10-K, accession 0001964738-26-000007], and the company carries $5.2 billion of net debt, about 2.5 times trailing operating income.
• Watch the next quarterly print for whether management holds adjusted EPS guidance toward the high end of $6.40 to $6.60 and for early evidence on the $1.0 billion buyback and the $850 million Acera Surgical acquisition.

Bull Case

The market is pricing Solventum as a business whose best years sit behind it. At $76.67 (July 10, 2026) the price works out to about nine times company-wide operating income, a level consistent with a company whose operating profit shrinks year after year. The fundamentals describe something different. Organic sales grew 2.1% in the first quarter and adjusted earnings per share rose 10.6%, and the trailing operating margin runs at 25.5%. Modest growth at a healthy margin is not a melting business. The gap between what the price assumes and what the operations are doing is the bull case in one sentence.

What the company actually is helps explain why the market struggles with it. Following the September 2025 divestiture of Purification and Filtration, Solventum is "organized into three reportable business segments": MedSurg, described in the 10-K as a provider of advanced wound care and surgical solutions "intended to accelerate healing, prevent complications and lower the total cost of care globally", Dental Solutions, and Health Information Systems [FY2025 10-K, accession 0001964738-26-000007]. The revenue base is balanced across geographies, with 56% of sales in the United States [FY2025 10-K, accession 0001964738-26-000007], and the customer relationships are sticky by design: the filing points to "long-tenured and collaborative customer relationships globally" that feed the product pipeline [FY2025 10-K, accession 0001964738-26-000007]. In Health Information Systems, revenue growth came from "adoption of our Solventum™ 360 Encompass™ and performance management solutions" [FY2025 10-K, accession 0001964738-26-000007], software that sits inside hospital revenue-cycle workflows and does not get ripped out casually.

Management is also doing the things a cheap, cash-generative company should do. The Purification and Filtration business went to Thermo Fisher for approximately $4.0 billion in cash, with proceeds directed primarily at debt reduction. A $1.0 billion share repurchase program began execution in January 2026, and the $850 million Acera Surgical acquisition ($725 million cash plus up to $125 million in contingent milestone payments) adds regenerative tissue technology to the largest segment. If the standalone cost structure normalizes while the buyback works on the share count, the earnings power at today’s multiple does the rest. Wedbush initiated the stock in June at Outperform with a $94 target, calling it a multi-catalyst special situation; that is one reading of the same arithmetic.

Bear Case

Start with how the cash is being spent, because a company two years into standing alone is doing a lot at once. Solventum carries $5.7 billion of gross debt, and its own filing names "the cost to service the debt we incurred in connection with the separation" among the risks to its market opportunity [FY2025 10-K, accession 0001964738-26-000007]. Against that backdrop, management launched a $1.0 billion buyback in January 2026 and agreed to pay $850 million for Acera Surgical, while the share count has actually drifted up about half a percent a year over the past three years. Buying back stock, buying a company, and servicing separation debt simultaneously is a capital-allocation program with no slack in it, and the GAAP income statement shows the strain: first-quarter GAAP earnings were $0.07 per share against $1.48 adjusted. The space between those two numbers is separation and restructuring cost, and it has to keep shrinking for the equity story to work.

The operating pressure is not hypothetical. MedSurg, at 58% of sales the segment that matters most, saw profitability decline on "higher product costs due to tariffs, logistics and a full year of supply agreement mark-ups from 3M" [FY2025 10-K, accession 0001964738-26-000007]. The company is also absorbing "higher costs associated with both initial stand-up and ongoing operations to support a standalone company" [FY2025 10-K, accession 0001964738-26-000007]. Inside Health Information Systems, the growth product is doing the work while "clinician productivity solutions declined primarily due to impacts from changing market conditions" [FY2025 10-K, accession 0001964738-26-000007]. A 25.5% trailing margin is the number the cheap-multiple argument rests on; tariffs, supply mark-ups, and standalone overhead all push against it.

The structural risks compound the margin question. The 10-K warns that "if Solventum faces an increase in costs or reduces its prices because of industry consolidation, or if Solventum loses customers as a result of consolidation" the business suffers [FY2025 10-K, accession 0001964738-26-000007], and hospital purchasing keeps consolidating. Dental Solutions faces Align Technology in orthodontics, and the filing describes the healthcare IT market as "highly competitive and dynamic" [FY2025 10-K, accession 0001964738-26-000007]. Meanwhile the price already sits below what even a steadily shrinking operating-profit stream would justify, which means the market is not being careless; it is charging for the possibility that margins compress from here. If organic growth stays near 2% and the margin gives back a few points, the multiple stops looking cheap and starts looking correct. Cheap because of what could deteriorate is a different proposition from cheap by oversight.

Valuation

At $76.67 the market pays about nine times company-wide operating income for Solventum, a price low enough that it sits below what even a 5% annual decline in operating profit would warrant at an 8.1% cost of capital. The bet embedded in the price, in other words, is not on growth at all; the price would be earned back even by a business in gentle retreat, and the company as reported is growing organically at 2.1% on $8,325 million of 2025 sales [FY2025 10-K, accession 0001964738-26-000007] at a 25.5% trailing operating margin. Against its healthcare peer set the multiple lands in the lower half of the range.

The methods we use to triangulate the price disagree in an unusual pattern. Peer-multiple comparisons land far above today’s price: on those lenses the stock trades at well under half of what comparable-company multiples would defend. The earnings-power view, which capitalizes current operating profit with no growth credited, lands essentially at the price. The forward-looking cash-flow view sits below it, with the price about 60% above what that method reaches, and the asset-value lenses find it expensive, with the price near three times where book-value-plus-profitability arithmetic lands. Read together: the price is supported by what the business earns today and by how peers are priced, not by balance-sheet value and not by aggressive growth assumptions. This is a value proposition resting on earnings durability, not a growth bet.

The balance sheet frames the downside. Net debt of $5.2 billion runs at about 2.5 times trailing operating income (roughly 3.0 times on an after-tax basis), the company is not burning cash, and the share count has been close to flat, drifting up about 0.5% a year over three years, a drift the newly launched buyback is positioned to reverse. Leverage at two and a half turns of operating income is serviceable for a business with recurring hospital and dental revenue, but it is real debt from the separation, and it is the reason the earnings-power support under the price matters more here than it would for a net-cash company. The one thing the price needs is for the 25.5% margin to hold while the standalone cost structure finishes normalizing.

Catalysts

The first quarter, reported May 5, 2026, set the near-term frame: sales of $2.01 billion were down 3.0% on the divested Purification and Filtration revenue, organic growth was 2.1%, adjusted EPS rose 10.6% to $1.48, and management reaffirmed full-year 2026 guidance including adjusted EPS toward the high end of $6.40 to $6.60. The next quarterly print, on the company’s roughly 90-day reporting cadence, is the next hard information event, and the items to check are the same ones the quarter raised: organic growth holding in the 2 to 3% range, the tariff and supply-cost drag on MedSurg margins, and progress narrowing the gap between GAAP and adjusted earnings.

Two capital moves are live. The $850 million Acera Surgical acquisition ($725 million cash, up to $125 million contingent on milestones) adds regenerative surgical biomaterials to MedSurg, and integration progress plus any disclosed revenue contribution will show up over the next two prints. The $1.0 billion share repurchase program began execution in January 2026; the share count line each quarter is the scoreboard.

Analyst positioning split in June. Wedbush initiated at Outperform with a $94 target, framing the stock as a multi-catalyst special situation, while Rothschild & Co Redburn opened coverage with a bearish stance on execution and margin-compression risk, and BTIG, Piper Sandler, and UBS trimmed targets. The consensus rating remains Buy with an average target near $84. The disagreement maps cleanly onto the fundamental question: whether the post-separation cost structure normalizes before the tariff and consolidation pressures eat the margin.

Peer Cohorts (Per Segment, With Filing Citations)

MedSurg (reported)

• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …country:US bdx:PharmaceuticalSystemsMember bdx:MedicalMember 2024-10-01 2025-09-30 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:PharmaceuticalSystemsMember bdx:MedicalMember 2024-10-01 2025-09-30 0000010795 us-gaap:OperatingSegmentsMember bdx:PharmaceuticalSystemsMember bdx:MedicalMember…
• FY2025 10-K: …us-gaap:NonUsMember bdx:UrologyandCriticalCareMember bdx:InterventionalMember 2023-10-01 2024-09-30 0000010795 us-gaap:OperatingSegmentsMember bdx:UrologyandCriticalCareMember bdx:InterventionalMember 2023-10-01 2024-09-30 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:UrologyandCriticalCareMember…
• BAX (BAXTER INTERNATIONAL INC)
• FY2025 10-K: …Africa, Latin America and Asia (except for Japan). 2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia and New Zealand. 3 Percent change in net sales at operational sales growth is a non-GAAP financial measure. See the section entitled "Non-GAAP Financial Measures" for…
• FY2025 10-K: …bax:AdvancedSurgeryMember bax:MedicalProductsAndTherapiesMember 2025-01-01 2025-12-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember country:US bax:MedicalProductsAndTherapiesMember 2024-01-01 2024-12-31 0000010456 us-gaap:OperatingSegmentsMember bax:AdvancedSurgeryMember us-gaap:NonUsMember…
• SNN (Smith & Nephew plc)
• FY2025 20-F: Implant, the guidance supports the notion that bioinductive implants can reduce the risk of re-tears21 and offer better patient outcomes.21 The HEALICOIL◊ family of shoulder anchors features an open architecture designed to facilitate healing and is available in our REGENESORB◊ material, which can be shown to be…
• FY2025 20-F: Smith+Nephew 2022. Summary of RENASYS EDGE pump mechanical and electronic reliability testing. Internal Report. CSD.AWM.22.069. 53 Smith+Nephew 2022. Summary of RENASYS EDGE pump cleaning, self-test and maintenance. Internal Report. CSD. AWM.22.068 310 Smith+Nephew Annual Report 2025 References from business unit…
• ICUI (ICU MEDICAL INC/DE)
• FY2025 10-K: …uncertainties and assumptions, including without limitation, the following: • our failure to compete successfully with our competitors and maintain market share; • significant decline in demand for our products; • our inability to fund substantial investment in product development and recover such investment through…
• FY2025 10-K: …in San Clemente, California, ICU was founded in 1984. Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. Since our inception we have grown organically and through…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …("Teleflex"), Cook Medical Incorporated ("Cook Medical"), Medtronic plc ("Medtronic"), Boston Scientific Corporation ("Boston Scientific"), and Becton, Dickinson and Company ("BD"). Our primary competitors in our cardiac intervention market are BD, Teleflex, Medtronic, Abbott Laboratories, Terumo Corporation, Edwards…
• FY2025 10-K: …categories to include our spine products under our OEM product category. Our spine products are used in the treatment of vertebral compression fractures and metastatic spinal tumors and in musculoskeletal biopsy procedures. Our spine product line includes the following product portfolios: vertebral augmentation,…
• ENOV (ENOV)
• FY2025 10-K: …is that when we use the tools of EGX to drive the implementation of these plans, we are able to uniquely provide customers with the world-class quality, delivery, cost and innovation they require. We believe that performance ultimately helps our customers and Enovis sustainably grow and succeed. Reportable Segments…
• FY2025 10-K: …orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators used for pain management and physical therapy products. Reconstructive Our Recon segment is a global medical technology business focused on developing, manufacturing, marketing,…
• ATRC (AtriCure, Inc.)
• FY2025 10-K: …a solution for soft-tissue closure that includes a suture loop coupled to a single-use disposable applier. The Lumitip™ dissector is used by surgeons to separate tissues to provide access to key anatomical structures that are targeted for ablation. Other enabling technologies include our Glidepath™ guides for…
• FY2025 10-K: …evaluates safety at 30 days post-procedure to demonstrate no increased risk with LAA exclusion during cardiac surgery, and efficacy over a minimum follow-up period of five years post procedure. In July 2025, we completed trial enrollment of 6,573 patients across 139 centers globally and patient follow-up remains…

Dental Solutions (reported)

• XRAY (DENTSPLY SIRONA Inc.)
• FY2025 10-K: Technology Solutions, (2) Essential Dental Solutions, (3) Orthodontic and Implant Solutions, and (4) Wellspect Healthcare. For the year ended December 31, 2025, the Company's net sales disaggregated by reportable segment and the product categories of these reportable segments as a percent of net sales were as follows:…
• FY2025 10-K: …and the Company sells products globally through its foreign subsidiaries to customers in approximately 140 countries. Dentsply Sirona has a long-established presence in the European market, particularly in Germany, Sweden, France, the United Kingdom ("UK"), Italy, and Switzerland. The Company also has a significant…
• ALGN (ALIGN TECHNOLOGY, INC.)
• FY2025 10-K: …of high technology locations. • Targeting growth opportunities with international orthodontists and GP customers, particularly with adopters of digital dentistry platforms by tailoring our sales and marketing strategies, manufacturing operations and resources around the unique needs of each customer channel. As we…
• FY2025 10-K: …cases worldwide, including in Costa Rica, China, Germany, Spain, Poland, and Japan, among others. By establishing and expanding our key operational activities in locations closer to our customers, we are creating an infrastructure that allows us to be responsive to local and regional needs, while providing global…
• NVST (ENVISTA HOLDINGS CORPORATION)
• FY2025 10-K: …patient access to high-quality dental care. Our customers include oral surgeons, periodontists, prosthodontists, and general dentists. Our Dental Implant Solutions brands have a long history of innovation, which include both the first documented case of a titanium dental implant being placed in a human and the…
• FY2025 10-K: …and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. We typically market these products directly to end-users through our commercial organization, and 84% of our 2025 sales for this segment were direct sales. In 2025, our Specialty Products & Technologies segment generated…
• ESTA (Establishment Labs Holdings Inc.)
• FY2025 10-K: …We believe these proprietary technologies that differentiate our Motiva Implants result in improved safety and aesthetic outcomes and thus drive our revenue growth. Since launching Motiva Implants in October 2010, the majority of our revenue has been generated from sales of our Motiva Implants. To date, our Motiva…
• FY2025 10-K: …as of December 31, 2025. One customer accounted for 17.0 % of the Company's trade accounts receivable balance as of December 31, 2024. The Company relies on Avantor, Inc. (formerly NuSil Technology, LLC), or Avantor, as the sole supplier of medical-grade silicone used in Motiva Implants. During the years ended…

Health Information Systems (reported)

• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …adversely impact us or our third-party sterilization providers. • IT system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, which could impair our ability or that of our customers, suppliers and other business partners to conduct business, result in the loss of…
• FY2025 10-K: …of information and technology ("IT") systems and related infrastructure, including services provided to us by third-party vendors to operate our business. We collect, use, store, transfer and otherwise process electronic information in our day-to-day operations, including personal, confidential, or proprietary…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties and other factors affecting our business, see Item 1A. Risk Factors in this report and our subsequent Quarterly Reports on Form 10-Q.…
• FY2025 10-K: …governments, as well those targeted towards our specific industry. More privacy and data security laws and regulations are being adopted and enforced, with increasingly significant fines and financial penalties for violations in the jurisdictions in which we conduct our operations. Compliance with these evolving and…
• SYK (STRYKER CORP)
• FY2025 10-K: …quality systems, labeling and post- market surveillance. Extended transition timelines were published in 2023 which range from May 2026 through December 2028 depending on the type of device and we are on track to meet these timelines. Initiatives to limit the growth of general healthcare expenses and hospital costs…
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• MDT (Medtronic plc)
• FY2025 10-K: Medicaid and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services provided to their patients. The ability of our customers to obtain appropriate reimbursement for products and services from third-party payors is critical because it affects which products customers…
• FY2025 10-K: …governmental interpretation and different cross border data transfer rules, compliance may require significant additional cost expenditures or changes in products or business that increase competition or reduce revenue. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant…
• ICUI (ICU MEDICAL INC/DE)
• FY2025 10-K: …lower reimbursements by governmental and private payors to our customers, which may adversely affect our business, financial condition and results of operations. EU Healthcare Reform Additional healthcare reform measures in the EU may be adopted in the future as well. For instance, in December 2021, Regulation (EU)…
• FY2025 10-K: …our or our collaborators', service providers' and contractors' ability to operate in certain jurisdictions or to collect, store, transfer, 26 use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. In the U.S.,…
• ITGR (INTEGER HOLDINGS CORPORATION)
• FY2025 10-K: …activities and technology licensing arrangements to support our growth in these markets. As our customers grow and consolidate, they seek suppliers who can offer broad product capabilities, manufacturing scale and facilitate speed to market. Our strategy aligns with enhancing our portfolio from both organic and…
• FY2025 10-K: …and government third-party payors. Internationally, healthcare reimbursement systems vary significantly. In some countries, medical centers are constrained by fixed budgets, regardless of the volume and nature of patient treatment. Other countries require application for, and approval of, government or third-party…
• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …health insurers and other third-party payors have delayed and otherwise adversely affected the demand and payment for surgical procedures and treatments involving our products and services, which adverse effects may continue, recur, and/or change in scope or magnitude in the future. Cyber attacks are becoming more…
• FY2025 10-K: …will have a material impact on our consolidated earnings, capital expenditures or competitive position. Data Privacy, Cyber and Artificial Intelligence Laws We are subject to evolving national, state, international and other data privacy and security laws and regulations that govern the collection, use, disclosure,…
• RMD (ResMed Inc.)
• FY2025 10-K: Act of 2009, or HITECH, which we collectively refer to as HIPAA, the Department of Health and Human Services, or HHS, has issued regulations, including the HIPAA Privacy, Security and Breach Notification Rules, to protect the privacy and security of protected health information, or PHI, used or disclosed by covered…
• FY2025 10-K: …profitability. • We are increasingly dependent on information technology systems and infrastructure. Failed, substandard or delayed efforts to improve our IT System infrastructure may result in disruption to our business or materially increased costs. • Actual or attempted breaches of security, unauthorized…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.